

1 1. A method for detecting a *Helicobacter pylori* infection, the method comprising
2 the steps of:

3 determining an integrity of a *Helicobacter pylori* nucleic acid present in
4 a patient sample; and

5 identifying the patient as having a current *Helicobacter pylori* infection
6 if the integrity of the nucleic acid exceeds a predetermined threshold.

1 2. The method of claim 1, wherein the identifying step comprises:

2 comparing the integrity of the *Helicobacter pylori* nucleic acid to an
3 integrity of a non-*Helicobacter pylori* nucleic acid.

1 3. The method of claim 2, wherein the non-*Helicobacter pylori* nucleic acid is a
2 patient nucleic acid.

1 4. The method of claim 2, wherein the non-*Helicobacter pylori* nucleic acid is an
2 *Escherichia coli* nucleic acid.

1 5. The method of claim 1, wherein the patient sample is selected from the group
2 consisting of stool, sputum, pancreatic fluid, bile, lymph, blood, urine, saliva, gastric
3 juice, and vomitus.

1 6. The method of claim 5, wherein the patient sample is stool.

1 7. The method of claim 5, wherein the patient sample is saliva.

1 8. The method of claim 5, wherein the *Helicobacter pylori* nucleic acid is a DNA.

1 9. The method of claim 1, comprising the further step of adding an ion chelator
2 to the patient sample such that the concentration of the ion chelator is at least 150
3 mM, thereby to preserve the integrity of the *Helicobacter pylori* nucleic acid.

1 10. A method for grading a *Helicobacter pylori* infection in a patient, the method
2 comprising the steps of:

Sub
A1

09755004-010501

Sub
A2

Sub
A3

09755004-010501

3 determining an amount of high-integrity *Helicobacter pylori* nucleic acid
4 present in a patient sample;

5 comparing said amount with at least two standards comprising high-
6 integrity *Helicobacter pylori* nucleic acid, each standard being indicative of a
7 different grade of *Helicobacter pylori* infection; and

8 grading a *Helicobacter pylori* infection based on said comparing step.

1 11. A method for grading a *Helicobacter pylori* infection in a patient, the method
2 comprising the steps of:

3 detecting a high-integrity *Helicobacter pylori* nucleic acid and a non-
4 *Helicobacter pylori* nucleic acid in a patient sample;

5 determining an amount of the high-integrity *Helicobacter pylori* nucleic
6 acid relative to the non-*Helicobacter pylori* nucleic acid in the patient sample;

7 comparing said amount with at least two standards of high-integrity
8 *Helicobacter pylori* nucleic acid relative to non-*Helicobacter pylori* nucleic
9 acid, each standard being indicative of a particular grade of a *Helicobacter*
10 *pylori* infection; and

11 grading a *Helicobacter pylori* infection based on said comparing step.

1 12. A method for monitoring progression of a *Helicobacter pylori* infection in a
2 patient, the method comprising the steps of:

3 determining a first amount of a *Helicobacter pylori* nucleic acid in a first
4 sample obtained from a patient;

5 determining a second amount of a *Helicobacter pylori* nucleic acid in a
6 second sample obtained from the patient;

7 comparing the first amount with the second amount; and

8 classifying the infection as diminishing if the second amount is less
9 than the first amount.

1 13. The method of claim 12, wherein the second sample is obtained no more than
2 thirty days after the first sample.

1 14. A method for evaluating a course of treatment for a *Helicobacter pylori*
2 infection, the method comprising the steps of:

3 obtaining a sample from a patient during a course of treatment or no
4 more than thirty days after the course of treatment;

5 amplifying a high-integrity *Helicobacter pylori* nucleic acid present in
6 the sample; and

7 identifying the patient as having a current *Helicobacter pylori* infection
8 if the high-integrity *Helicobacter pylori* nucleic acid is present in the sample.

1 15. A method for evaluating the efficacy of a proposed treatment regimen for a
2 *Helicobacter pylori* infection, the method comprising the steps of:

3 obtaining, from test patients diagnosed with an *Helicobacter pylori*
4 infection, a test set of samples during the course of a proposed treatment
5 regimen or no more than thirty days after the course of the proposed
6 treatment regimen;

7 obtaining, from control patients diagnosed with an *Helicobacter pylori*
8 infection, a control set of samples during the course of a control treatment
9 regimen or no more than thirty days after the course of the control treatment
10 regimen;

11 amplifying a high-integrity *Helicobacter pylori* nucleic acid present in
12 the samples; and

13 comparing the amount of high-integrity *Helicobacter pylori* nucleic acid
14 present in the test set of samples to the amount of high-integrity *Helicobacter*
15 *pylori* nucleic acid present in the control set of samples.

1 16. A method for diagnosing a gastric disease in a patient, the method comprising
2 the steps of:

09755004-010501

3 detecting a high-integrity *Helicobacter pylori* nucleic acid in a patient
4 sample; and

5 identifying the patient as having a gastric disease caused by a
6 *Helicobacter pylori* infection if the high-integrity *Helicobacter pylori* nucleic
7 acid is present in the sample.

10
17. A method for detecting a *Helicobacter pylori* infection in a patient, the method
2 comprising the steps of:

3 amplifying, from a patient sample,

4 a first *Helicobacter pylori* nucleic acid at least 200 nucleotides in
5 length,

6 a second *Helicobacter pylori* nucleic acid at least 400
7 nucleotides in length, and

8 a third *Helicobacter pylori* nucleic acid at least 600 nucleotides
9 in length;

10 detecting the amplified first, second, and third *Helicobacter pylori*
11 nucleic acids; and

12 identifying the patient as having a *Helicobacter pylori* infection if the
13 amplified first, second, and third *Helicobacter pylori* nucleic acids are
14 detected.

Sub A4
1 18. A method for detecting a *Helicobacter pylori* infection in a patient, the method
2 comprising the steps of:

3 determining the integrity of patient nucleic acids in a patient sample
4 comprising shed cells or cellular debris; and

5 identifying the patient as having disease if the integrity of the patient
6 nucleic acids exceeds a predetermined threshold.

ADD
A5

ADD
B4